Survodutide
Common Reported Dosing in Clinical Trials
Survodutide is administered as a once-weekly subcutaneous injection (typically in the abdomen, thigh, or upper arm). Dosing always involves slow titration to improve gastrointestinal tolerability.
Phase 2 obesity trial (46 weeks, no diabetes):
Doses tested: 0.6 mg, 2.4 mg, 3.6 mg, 4.8 mg once weekly.
Mean weight loss (planned treatment): up to -14.9% at 4.8 mg (vs. -2.8% placebo).
In "actual treatment" analysis (accounting for titration): up to -18.7% at 4.8 mg.
Phase 2 MASH trial (48 weeks):
Doses: 2.4 mg, 4.8 mg, 6.0 mg once weekly.
MASH resolution without fibrosis worsening: 47–62% (vs. 14% placebo), with strong liver fat reduction.
Ongoing Phase 3 trials (e.g., SYNCHRONIZE-1/2 for obesity, up to 76 weeks):
Target maintenance doses: 3.6 mg or 6.0 mg once weekly.
Flexible, extended titration schedule (often over 10–20+ weeks) with options to delay increases, reduce by one step, or pause for tolerability (especially GI side effects).
Example titration protocol (adapted from research/vial reconstitution guides; varies by trial and individual tolerance):
Weeks 1–2: 0.6 mg
Weeks 3–4: 1.2 mg
Weeks 5–6: 1.8 mg
Weeks 7–8: 2.4 mg
Weeks 9–10: 3.6 mg
Weeks 11+: Up to 4.8–6.0 mg (if tolerated)
Key Potential Benefits of Survodutide
Significant and Progressive Weight Loss
Achieves mean body weight reductions of up to 14.9% (planned treatment) to 18.7% (actual treatment) at 46 weeks in adults with overweight or obesity without diabetes at the highest doses (e.g., 4.8 mg weekly).
High responder rates, with up to 40% of participants achieving ≥20% weight loss, 54–69% achieving ≥15% or ≥10% loss, and over 80% achieving ≥5% loss in key cohorts.
Demonstrates continued weight reduction without a clear plateau at 46 weeks in Phase 2 studies, suggesting potential for further benefits with longer treatment duration.
Enhanced Satiety, Appetite Control, and Energy Expenditure
GLP-1 receptor activation promotes strong feelings of fullness, reduces hunger signals, delays gastric emptying, and suppresses cravings through central and gut-mediated pathways.
Glucagon receptor activation increases energy expenditure and fat oxidation, complementing GLP-1 effects to drive greater overall caloric deficit and metabolic efficiency.
Dual mechanism provides multi-pathway reinforcement of appetite regulation and energy balance, supporting sustained adherence and more robust weight management compared to single-pathway agents in research models.
Improved Glycemic Control and Type 2 Diabetes Management
Reduces HbA1c by up to 1.5–1.88 percentage points after 16 weeks in people with type 2 diabetes, with effects comparable to or approaching those of semaglutide in head-to-head Phase 2 data.
Lowers fasting glucose, insulin levels, and improves insulin sensitivity (e.g., substantial reductions in HOMA-IR index), supporting better overall glucose regulation.
Offers potential for prediabetes reversal or enhanced diabetes control when added to background therapies like metformin.
Favorable Cardiometabolic and Liver Health Improvements
Reduces waist circumference, systolic and diastolic blood pressure, plasma triglycerides, and other lipid markers alongside weight loss.
In MASH (metabolic dysfunction-associated steatohepatitis) Phase 2 data, leads to significant improvements in liver fat content, liver stiffness, fibrosis markers, and overall MASH resolution without worsening of fibrosis (up to 83% response rates in some analyses).
Supports reductions in inflammatory and hepatic stress markers, contributing to broader cardiometabolic risk factor improvement.
Potential Preservation of Lean Mass and Body Composition Benefits
Glucagon component promotes fat-specific oxidation and energy use, helping drive weight loss with potentially favorable effects on body composition (reduced fat mass while supporting metabolic health).
Associated with improvements in physical function, quality of life measures, and reduced features of metabolic syndrome in trial populations.
Synergistic Advantages of Dual GLP-1/Glucagon Agonism
Combines GLP-1-driven appetite suppression and glucose control with glucagon-mediated increases in energy expenditure and hepatic fat metabolism for complementary effects.
May offer broader coverage of metabolic pathways than GLP-1 monotherapy, potentially leading to greater total weight loss, sustained efficacy, and additional liver and cardiometabolic benefits.
Positions as a promising option for individuals with obesity, type 2 diabetes, or MASH, with ongoing Phase 3 trials (SYNCHRONIZE and LIVERAGE programs) evaluating longer-term outcomes up to 72–76 weeks.
